Abstracts tagged "Cohort Study"

Abstract Number: 0137 • ACR Convergence 2025
Landscape of Primary Antiphospholipid Syndrome: Clinical Spectrum, Serology, and Predictors of Damage in a Single Center Cohort of 233 Patients
RITESH KUMAR MISHRA¹, SUBIN PHILIP², JAIDEV MENON², RIZWANA NAUSHAD², AISHWARYA GOPAL³, CHRISTINA MARIASELVAM², Chengappa Kavadichanda², Molly mary Thabah³ and VIR SINGH NEGI², ¹JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, Bhubaneswar, India, ²JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, PUDUCHERRY, Puducherry, India, ³JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, PUDUCHERRY, India
Background/Purpose: Primary Antiphospholipid Syndrome (APS) a systemic autoimmune prothrombotic disorder with long-term consequences. While secondary APS is well studied, large real-world cohorts of primary APS…
Abstract Number: 2650 • ACR Convergence 2025
LFA-REAL Outperforms SLEDAI and BILAG in Detecting Clinical Change in Lupus Activity
Alberto Nordmann-Gomes¹, Leila Khalili², Cynthia Aranow³, Meghan mackay⁴, Mimi Kim⁵, Diane Kamen⁶, Cristina Arriens⁷, Maya Souvignier⁸, Wei Tang⁹, Stephen Suh⁸, Maria Dall'Era¹⁰, Joan Merrill¹¹ and Anca Askanase², ¹Columbia University Irving Medical Center, New York, NY, ²Columbia University Medical Center, New York, NY, ³Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, ⁴Feinstein Institutes for Medical Research, Manhasset, NY, ⁵Albert Einstein College of Medicine, Bronx, NY, ⁶Medical University of South Carolina, Johns Island, SC, ⁷Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Columbia University Irving Medical Center, New York City, NY, ⁹Westchester Medical Center, Valhalla, NY, ¹⁰Division of Rheumatology, University of California, San Francisco, CA, ¹¹Oklahoma Medical Research Foundation, Oklahoma
Background/Purpose: Disease activity measures in SLE have important limitations that restrict their performance in clinical practice and research. The Lupus Foundation of America-Rapid Evaluation of…
Abstract Number: 2382 • ACR Convergence 2025
Autoimmune Hemolytic Anemia in SLE: A Real-World National Cohort Study
Bana Shawareb¹, Muhannad Haddadin¹, lindsay Frumker², Keri Ann Pfeil³, Meghan Gump³, Ansaam Daoud⁴ and Omer Pamuk⁵, ¹Cleveland Clinic Akron General, Akron, OH, ²Case Western Reserve University, Cleveland, ³University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, ⁴Case Western Reserve University/University Hospitals, Cleveland, OH, ⁵University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: Autoimmune hemolytic anemia (AIHA) is a rare but serious hematologic manifestation of SLE. The prognostic implications of AIHA, particularly long-term mortality and organ involvement,…
Abstract Number: 2068 • ACR Convergence 2025
Comparing characteristics, diagnostics, and treatment in people with different idiopathic inflammatory myopathies using a large representative cohort
Michael George¹, Thomas Riley¹, Ellen Romich², Emily Holladay³, Tim Beukelman⁴, Shanette Daigle⁵, Amy Mudano⁵, Fenglong Xie⁶, Xiang Guo⁷, Nicole Kulisek⁸, Arne Yndestad⁹, Ashraf Chaudhary⁸ and Jeffrey Curtis¹⁰, ¹University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Media, PA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Foundation for Advancing Science Technology Education and Research, Hoover, AL, ⁵Foundation for Advancing Science, Technology, Education and Research (FASTER), Hoover, AL, ⁶The University of Alabama at Birmingham, Birmingham, AL, ⁷Pfizer, Inc, New York, NY, ⁸Pfizer, Inc, Collegeville, PA, ⁹Pfizer Inc, Oslo, Norway, Oslo, Norway, ¹⁰Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL
Background/Purpose: Studies of idiopathic inflammatory myopathies (IIM) are often based on the analysis of single cohorts at academic centers. We aimed to identify potential gaps…
Abstract Number: 1788 • ACR Convergence 2025
Manganese-associated Single-nucleotide Polymorphisms are Associated with Radiographic Knee Osteoarthritis: The Johnston County Osteoarthritis Project
Griffin Sonaty¹, Carolina Alvarez², Liubov Arbeeva³, Joanne Jordan¹, Brian Diekman⁴, Doug Phanstiel¹, Richard Loeser⁵ and Amanda Nelson¹, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Miami, FL, ³University of North Carolina, Chapel Hill, Carrboro, NC, ⁴Univesity of North Carolina at Chapel Hill, Chapel Hill, NC, ⁵University of North Carolina, Chapel Hill, NC
Background/Purpose: Trace elements may be differentially associated with osteoarthritis (OA) risk. Single-nucleotide polymorphisms (SNPs) have been found to correlate to cumulative exposure level, free of…
Abstract Number: 1536 • ACR Convergence 2025
Evaluating Systemic Lupus Erythematosus Remission Among Patients Initiating Belimumab in a Real-World Setting in the USA
Aarat M Patel¹, Renee L. Gennarelli², Temitope Bello², Ali Bonakdar² and Karen Worley³, ¹GSK, US Medical Affairs, Durham, NC, ²Cencora, Real-World Evidence, Conshohocken, PA, ³GSK, Global Real-World Evidence & Health Outcomes Research, Collegeville, PA
Background/Purpose: The Definition Of Remission In SLE (DORIS) criteria were developed to provide alignment on defining remission in patients with SLE.1,2 Belimumab (BEL) treatment increases…
Abstract Number: 1279 • ACR Convergence 2025
Whole Blood Gene Expression Defined Subgroups of Treatment Naïve Children and Adolescents with Childhood-onset Systemic Lupus Erythematosus.
Reagan Reid¹, Huayun Hou², Isha Datar², Daniela Dominguez³, Andrea Knight⁴, Deborah Levy⁵, Lawrence Ng⁶, Zhaoyu Ding², Michael Wilson², Lauren Erdman⁷, Eleanor Pullenayegum² and Linda Hiraki⁵, ¹The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ²SickKids Research Institute, Toronto, ON, Canada, ³The Hospital for Sick Children, Toronto, Canada, ⁴Hospital for Sick Children, Toronto, ON, Canada, ⁵The Hospital for Sick Children, Toronto, ON, Canada, ⁶The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada, ⁷University of Cincinnati, Cincinnati, OH
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) is a clinically and genetically heterogeneous disease. We aimed to define subgroups of new diagnosis patients based on treatment…
Abstract Number: 1091 • ACR Convergence 2025
Safety Profile of ICIs in Patients with Rheumatoid Arthritis: Results from a Propensity Score-Matched Cohort Study
Betul Ibis¹, Furkan Bahar¹, Yu-Che Lee², Ko-Yun Chang³, Yu Chang⁴ and Cho-Han Chiang⁵, ¹Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, ²University at Buffalo, Buffalo, NY, ³National Jewish Health, Denver, CO, ⁴National Cheng Kung University Hospital, Tainan, Taiwan (Republic of China), ⁵Mount Auburn Hospital, Harvard Medical School, Cambridge
Background/Purpose: Immune-related adverse events (irAEs) are a significant concern for patients receiving immune checkpoint inhibitors (ICIs), particularly those with pre-existing rheumatoid arthritis (RA). Managing ICIs…
Abstract Number: 0734 • ACR Convergence 2025
Glucocorticoid Exposure and Comorbidity Profile in Patients with Polymyalgia Rheumatica and Giant Cell Arteritis: a multi-country cohort study
Julie Mouchet¹, Lauren Revie², Tim Nguyen³, Liwei Zhao⁴, Valeria Jordan M.⁵, G S Ramakrishna⁶, Linda Grinnell-Merrick³, Atif Adam⁷ and Minouk Schoemaker⁸, ¹Novartis Pharma AG, Basel, Switzerland, ²IQVIA, EMEA, London, United Kingdom, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴IQVIA, Real World Solutions, Mölndal, Sweden, ⁵Novartis Pharmaceuticals Corporation, Tenafly, NJ, ⁶Novartis Healthcare Private Limited, Hyderabad, India, ⁷IQVIA Inc, Boston, ⁸IQVIA, Real World Solutions, Amsterdam, Netherlands
Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are systemic inflammatory conditions that predominantly affect individuals ≥50 years of age. The conditions share overlapping…
Abstract Number: 0330 • ACR Convergence 2025
Prevalence of Radiographic and Symptomatic Osteoarthritis, and Ultrasound Features at the Knee: The Johnston County Health Study
Maya Patel¹, Carolina Alvarez², Todd Schwartz³, Tessa Walker¹, Serena Savage-Guin¹, Jordan Renner¹, Jonathan Samuels⁴, Janice Lin⁵, Minna Kohler⁶, Catherine Bakewell⁷, Yvonne Golightly⁸ and Amanda Nelson¹, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Miami, FL, ³University of North Carolina-Chapel Hill, Chapel Hill, NC, ⁴NYU Langone, Rye Brook, NY, ⁵Stanford University, Palo Alto, CA, ⁶Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁷Intermountain Healthcare, Salt Lake City, UT, ⁸University of Nebraska Medical Center, Omaha, NE
Background/Purpose: To report sex and BMI differences among ultrasound (US) features of knee osteoarthritis (KOA), patient-reported symptoms (Ksx), radiographic KOA (rKOA), and symptomatic KOA (sxKOA),…
Abstract Number: 0582 • ACR Convergence 2025
Long-Term Efficacy and Safety of Tofacitinib in Active Axial Spondyloarthritis: Experience from a Tertiary Care Center in South India
Prabhu Vasantha Kumar¹, John Mathew², Ashish Jacob Mathew³ and Ruchika Goel², ¹Christian Medical College, Vellore, Tamil Nadu, India, Vellore, Tamil Nadu, India, ²Christian Medical College, Vellore, Tamil Nadu, India, ³Christian Medical College, Vellore, India
Background/Purpose: Despite the good efficacy of bDMARDs in nearly 60% of patients with axial spondyloarthritis (AxSpA), high costs limit their use in resource-limited settings. Few…
Abstract Number: 2607 • ACR Convergence 2025
ERS-RA as a Tool for Cardiovascular Risk Prediction in Established Rheumatoid Arthritis: An External Validation
Misti Paudel¹, Katherine Liao², Jon Giles³, Joan Bathon⁴, Hongshu Guan⁵, Brendan Everett⁶, Leah Santacroce⁷, Nancy Shadick⁸, Michael Weinblatt⁹, Pamela Rist⁶ and Daniel Solomon¹⁰, ¹Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ²Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Boston, MA, USA, Boston, MA, ³Cedars Sinai Medical Center, Los Angeles, CA, ⁴Columbia University, NEW YORK, NY, ⁵Brigham and Women's Hospital/ Harvard Medical School, Boston, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Brigham & Women's Hospital, Boston, MA, ⁹Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ¹⁰Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA
Background/Purpose: The Expanded Risk Model for Rheumatoid Arthritis (ERS-RA) incorporates traditional CV risk factors and RA-related measures of disease activity and has demonstrated better performance…
Abstract Number: 2349 • ACR Convergence 2025
Classification of “Difficult-to-Manage Axial Spondyloarthritis”: A Real-World Cohort Study Evaluating the ASAS 2024 Criteria Over Time
Gözde Sevgi Kart bayram¹, Muhammed Çağrı Akdemir², Mustafa Ekici³, Gizem Ayan⁴, Büşra Fırlatan Yazgan¹, Erdinç Ünaldı³, Buğu Bulat¹, Ali Aytuğ Kuştaş³, Ali Akdoğan⁵, Omer Karadağ⁵, Şule Apraş Bilgen¹, Ali İhsan Ertenli¹, Sedat Kiraz³, Umut Kalyoncu¹ and Levent Kılıç¹, ¹Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara, Turkey, ²Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey, Ankara, Turkey, ³Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara, Ankara, Turkey, ⁴Ankara Research and Training Hospital, Ankara, Turkey, ⁵Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara
Background/Purpose: The concept of difficult-to-manage axial spondyloarthritis (D2M-axSpA)[1], may vary over time. Transitions between D2M and non-D2M classifications throughout the disease course remain unclear. This…
Abstract Number: 2060 • ACR Convergence 2025
Treatment Patterns And Drug Use In Idiopathic Inflammatory Myopathies. Description Of The First Year After Diagnosis In A Swedish Myositis Cohort.
Irene Peralta-García¹, Naz Haque², Dag Leonard³, Anna Glasin⁴, Silva Puksic⁵, Balsam Hanna⁶, My Axelhed⁷, Theodoros Lappas⁵, Farbicio Espinosa Ortega¹, Karin Lodin¹, NIls Eckerdal², Helene Alexanderson⁸, Elizabeth Hsia⁹, Federico Zazzetti¹⁰, Ingrid Lundberg¹¹ and Marie Holmqvist¹, ¹Karolinska Institutet, Clinical Epidemiology Division, Department of Medicine Solna. Karolinska University Hospital, Medical Unit of Gastroenterology, Dermatology, Rheumatology. Theme Inflammation and Ageing, Stockholm, Sweden, ²Karolinska Institutet, Clinical Epidemiology Division, Department of Medicine Solna, Stockholm, Sweden, ³Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ⁴Rheumatology Department, Linköping Hospital, LInköping, Sweden, ⁵Rheumatology Department, Örebro University Hospital, Örebro, Sweden, ⁶Rheumatology Department, Sahlgrenska University Hospital, Gothenburg, Sweden, ⁷Rheumatology Department, Västmanlands Hospital, Västerås, Sweden, ⁸Karolinska University Hospital, Stockholm, Sweden, ⁹Johnson & Johnson, Spring House, PA, ¹⁰Johnson & Johnson, Horsham, PA, USA, Ambler, PA, ¹¹Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Due to the rarity and heterogeneity of idiopathic inflammatory myopathies (IIM), we lack robust randomized trials to guide treatment decisions. Most of current practice…
Abstract Number: 1747 • ACR Convergence 2025
Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease or bronchiectasis: A matched cohort study
QIANRU ZHANG¹, Ying Qi², Xiaosong Wang³, Gregory McDermott⁴, Sung Hae Chang⁵, Mark Chaballa⁶, Vadim Khaychuk⁷, Misti Paudel⁸ and Jeffrey Sparks⁹, ¹Brigham and Women’s Hospital/Beijing Tsinghua Changgung Hospital, Cambridge, MA, ²Brigham and Women’s Hospital, Boston, ³Brigham and Women's Hospital, Natick, MA, ⁴Brigham and Women's Hospital, Brookline, MA, ⁵Soonchunhyang University College of Medicine, Cheonan, MA, South Korea, ⁶Bristol Myers Squibb, Princeton, NJ, ⁷Bristol Myers Squibb, Pennington, NJ, ⁸Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁹Brigham and Women's Hospital, Boston, MA
Background/Purpose: RA-associated lung disease (RA-LD), including RA-associated interstitial lung disease (RA-ILD) and RA-associated bronchiectasis (RA-BR), contributes significantly to morbidity and mortality in RA patients. RA…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].